On June 24, 2019 Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, reported that the U.S. Patent and Trademark Office ("USPTO") and the European Patent Office ("EPO") have issued allowances of patent applications relating to xB3 technology (Press release, biOasis, JUN 24, 2019, View Source [SID1234537254]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Both the USPTO and EPO have issued allowances of the Company’s patent applications relating to iduronate-2-sulfatase ("IDS") polypeptide / xB3 conjugates. The patent applications relate to the IDS/xB3 fusion conjugates as well as pharmaceutical compositions containing the fusion conjugates. The IDS/xB3 conjugates may be used in treating lysosomal storage diseases such as Hunter Syndrome.
The EPO has issued an allowance of the Company’s patent application relating to trastuzumab/xB3 fusion conjugates. The patent application relates to the trastuzumab/xB3 fusion conjugates as well as pharmaceutical compositions containing the fusion conjugates. The trastuzumab/xB3 conjugates may be used in treating a variety of diseases, for example, a HER2-overexpressing metastatic breast cancer.
"We are excited about the issuance of allowance of these patent applications by the USPTO and EPO, which enhance the strength of our intellectual property protection around our core assets, especially with respect to our lead program xB3-001, potential treatments for lysosomal storage disorders and our commercial licensing strategy," said Company Chair and Chief Executive Officer, Deborah Rathjen, Ph.D. "These patents reaffirm the overall value of Bioasis’ xB3 platform technology as we work to advance our programs for difficult-to-treat diseases of the central nervous system by delivering therapeutics across the blood-brain barrier."